India's Silent Liver Crisis: 38.6% Have Fatty Liver Disease, Experts Warn
Most individuals rarely consider their liver's health until significant problems emerge. By that critical point, the organ has often been deteriorating silently for years. This unsettling reality defines fatty liver disease, explaining why a condition scarcely recognized in India two decades ago has escalated into one of the nation's most urgent health emergencies.
The statistics are impossible to overlook. More than one in three Indians currently lives with metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver. This is not merely an issue of diet or weight. It is intricately connected to diabetes, cardiovascular disease, insulin resistance, and a genetic predisposition that renders South Asians particularly susceptible, even at body weights considered normal by Western benchmarks.
The Metabolic Storm Fueling India's Liver Disease Epidemic
To comprehend this surge and identify realistic solutions, we consulted Air Cmde (Dr.) Bhaskar Nandi, Director and Head of Gastroenterology, Hepatology and Endoscopy at Sarvodaya Hospital, Faridabad. With years of experience, he has observed this disease progressing undetected in patients showing no obvious symptoms, no dramatic weight gain, and no suspicion their liver was compromised—until it was too late.
"India is caught in a metabolic storm, and the liver is absorbing the worst of it," states Air Cmde (Dr.) Bhaskar Nandi. "The collision of rapid urbanization, increasingly sedentary occupations, calorie-rich diets, and a genetic tendency toward insulin resistance has created ideal conditions for fatty liver disease to thrive. India now hosts one of the world's largest MASLD patient populations, with an estimated pooled prevalence of 38.6%."
He highlights the danger's scope, referencing a 2026 community-based study in The Lancet Regional Health – Southeast Asia Journal. Using data from the Phenome India group across 27 cities, it found over one-third of individuals had MASLD, with notable regional variations necessitating larger, longitudinal studies.
The Critical Link Between Fatty Liver, Diabetes, and Heart Risk
Air Cmde (Dr.) Bhaskar Nandi emphasizes that MASLD should not be viewed as an isolated liver issue. "It is fundamentally a manifestation of metabolic dysfunction with consequences extending far beyond the liver," he explains. "MASLD patients face heightened risks of developing diabetes, heart disease, chronic kidney disease, and other cancers, with cardiovascular complications being a leading cause of mortality rather than liver damage itself."
The unifying factor is insulin resistance, which drives fat accumulation in the liver while simultaneously accelerating atherosclerosis and vascular damage. Among MASLD patients, 20% present with cardiovascular complications at diagnosis, carrying a 60% higher risk of cardiovascular events—a risk independent of traditional factors like hypertension, smoking, and high cholesterol.
In India, where approximately 77 million people have type 2 diabetes and nearly 25 million are prediabetic, an estimated 70% of them also have MASLD. This overlap is not coincidental but mechanistic, compelling clinicians managing diabetes or heart conditions to proactively screen for liver disease as part of standard care.
How Elevated Blood Sugar and Obesity Silently Accelerate Liver Damage
Air Cmde (Dr.) Bhaskar Nandi notes the liver's early silence as precisely what makes MASLD perilous in India, where metabolic disorders often remain unmanaged for years. Persistently high blood sugar promotes fat deposition in liver cells through de novo lipogenesis, a process converting excess glucose into fat. This fat accumulation triggers oxidative stress and inflammation, advancing to more severe conditions like steatohepatitis (MASH) and potentially cirrhosis or hepatocellular carcinoma.
Particularly alarming is the phenomenon of lean MASLD, where patients with normal or near-normal body weight develop significant liver disease. "India exhibits a unique MASLD phenotype: a high prevalence of lean NAFLD, affecting 39.7% of chronic liver disease patients, with marked insulin resistance despite lower BMI, exacerbated by socioeconomic constraints and diagnostic delays," he details.
A 2024 meta-analysis of 14 studies involving over 94,000 patients revealed that individuals with lean MASLD face a higher all-cause mortality risk than those with overweight or obesity and MASLD. This challenges the widespread assumption that fatty liver disease concerns only the visibly obese, representing a critical gap in public health communication.
Early Warning Signs Routinely Overlooked in Daily Life
The most hazardous aspect of MASLD is its silence. In most early-stage cases, no symptoms prompt a doctor's visit—no pain, jaundice, or obvious physical signs. By the time symptoms manifest, the disease has frequently progressed substantially.
Nevertheless, subtle signals warrant attention. Commonly reported symptoms include persistent, unexplained fatigue unrelieved by sleep. Vague discomfort in the upper right abdomen, unexplained weight gain around the midsection, or a sensation of fullness can also serve as early indicators. However, the most actionable warning often appears in routine blood tests: mildly elevated liver enzymes (ALT or AST) frequently dismissed as insignificant.
Fatty liver disease does not await middle age or obesity to announce itself. Anyone with risk factors such as diabetes, high triglycerides, hypertension, central obesity, or a family history of metabolic disease who exhibits mildly abnormal liver function tests should seek further evaluation without waiting for symptoms.
The Vital Role of Early Screening and Lifestyle Changes in Reversing Progression
The encouraging news about MASLD is its reversibility in early stages. Timely screening—especially for individuals with risk factors like obesity or diabetes—can facilitate early detection. Lifestyle modifications including weight management, a balanced diet, regular physical activity, and blood sugar control can substantially reduce liver fat and halt disease advancement.
Why Preventive Healthcare and Awareness Are Crucial to Averting Complications
MASLD is a silent disease often undetected until advanced stages. Fostering awareness and promoting preventive healthcare are essential to mitigating long-term burdens. Early intervention can prevent severe complications like cirrhosis and liver cancer, ultimately lowering healthcare costs and enhancing quality of life. A proactive, rather than reactive, approach is key to addressing this expanding public health challenge.
Medical Expert Consulted: This article incorporates expert insights from Air Cmde (Dr.) Bhaskar Nandi, Director and Head of Gastroenterology, Hepatology and Endoscopy at Sarvodaya Hospital, Faridabad, explaining why fatty liver is becoming prevalent among Indians, its symptoms, and prevention strategies.
